Cluster headache management: current landscape & emerging therapies

Cluster headache, a rare and severe form of headache disorder, represents the most common trigeminal autonomic cephalalgia. Due to its…

Date: 16th January 2024

Evolving perspectives in MOGAD: a comprehensive research update

Myelin oligodendrocyte glycoprotein antibody-associated disorder (MOGAD) is characterized by relapsing episodes of severe immune-mediated demyelination in deep white matter tracts….

Date: 20th December 2023

Cluster headache management: current landscape & emerging therapies

Cluster headache, a rare and severe form of headache disorder, represents the most common trigeminal autonomic cephalalgia. Due to its…

Date: 16th January 2024

Evolving perspectives in MOGAD: a comprehensive research update

Myelin oligodendrocyte glycoprotein antibody-associated disorder (MOGAD) is characterized by relapsing episodes of severe immune-mediated demyelination in deep white matter tracts….

Date: 20th December 2023

Artificial intelligence: a new era in neurology

The integration of artificial intelligence (AI) into the field of neurology has opened the door to unprecedented advancements. From facilitating…

Date: 9th August 2023

The wearables revolution in neurology

Neurologists and researchers are increasingly harnessing the power of wearables to gather real-time, high-quality data about patients’ neurological conditions. From…

Date: 2nd August 2023

α-syn in Parkinson’s disease: cause, biomarker, and treatment target

The causative nature of alpha-synuclein (α-syn) accumulation in Parkinson’s disease pathophysiology has been a subject of debate among researchers, ever…

Date: 25th July 2023

Biomarkers for disease progression and treatment response in MS

Biomarker development and discovery have been an important point in multiple sclerosis (MS) research for many years. Neurofilament light (NfL)…

Date: 29th March 2023

Debating bridging thrombolysis at ISC 2023

Whether the addition of intravenous thrombolysis (IVT) adds benefit beyond what can be achieved with mechanical thrombectomy (MT) alone is…

Date: 10th March 2023

Current and future therapeutic approaches in narcolepsy

Narcolepsy is a chronic neurological disorder of rapid onset eye movement (REM) sleep, affecting the sleep-wake cycle in the brain….

Date: 14th February 2023

Emerging treatment approaches for Parkinson’s disease

Parkinson’s disease (PD) is the second most prevalent neurodegenerative disease, and thus far, only efficacious symptomatic treatments have been developed,…

Date: 3rd February 2023

Research challenges and treatment updates in pediatric migraine

Headaches in children and adolescents have high incidence and prevalence rates, significantly impacting the quality of life and ability to…

Date: 27th January 2023

Seizures can promote more seizures through maladaptive myelination, new findings suggest

Myelin – the insulating layer surrounding neuronal axons – is essential for neuronal function. Once thought to be quite unchanged…

Date: 12th January 2023

The emergence of psychedelic-assisted therapies

Emerging research into the use of psychedelic-assisted therapies to treat a broad spectrum of neurological disorders has sparked great interest…

Date: 3rd January 2023

Pregnancy management in MS and NMOSD

Multiple sclerosis (MS) and neuromyelitis optica spectrum disorders (NMOSD) are chronic conditions of the central nervous system, predominantly affecting women…

Date: 25th November 2022

Debating intravenous and intra-arterial thrombolysis use in ischemic stroke

Since the landmark clinical trials in 2015, mechanical thrombectomy (MT) has become the gold standard management approach for acute ischemic…

Date: 17th November 2022

MS genetics and environment: new findings

With its prevalence growing globally, multiple sclerosis (MS) is the most common disabling neurologic disease to affect young adults, especially…

Date: 31st October 2022

Key trials in Huntington’s disease: SAGE-718, pridopidine, PTC518, & ANX005

Huntington’s disease (HD) is an autosomal dominant neurodegenerative disorder, caused by a CAG expansion in the huntingtin (HTT) gene. The…

Date: 19th October 2022

New horizons in hyperkinetic movement disorders

Hyperkinetic movement disorders (HMDs) are characterized by the presence of excessive, abnormal, and involuntary movements and can be isolated or…

Date: 13th October 2022

Update on cenobamate: long-term and subgroup analyses

Cenobamate is an investigational antiepileptic drug with a unique dual mechanism of action: it acts via the reduction of persistent…

Date: 7th October 2022

Novel targets for therapeutic intervention in movement disorders

The development of disease-modifying therapies and the identification of novel actionable targets are at the forefront of research in movement…

Date: 30th September 2022

Improving ALS management: diagnosis and treatment

Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease with highly variable clinical features and prognosis, making the diagnosis challenging. And…

Date: 9th September 2022

Broadening the use of thrombectomy in stroke management

For acute ischemic stroke with large vessel occlusion, endovascular thrombectomy (EVT) has emerged as the gold standard of care, yet…

Date: 2nd September 2022

Complement inhibitors and FcRn antagonists for myasthenia gravis

Despite existing symptomatic, immunomodulatory, and immunosuppressive therapies, significant unmet needs in myasthenia gravis (MG) treatment remain. Advances in drug development…

Date: 19th August 2022

Novel imaging biomarkers in MS diagnosis and prognostication

Magnetic resonance imaging (MRI) has emerged as a powerful, noninvasive tool for diagnosis, prognostication, and treatment monitoring in multiple sclerosis…

Date: 18th August 2022

Latest guidance on pregnancy and breastfeeding in epilepsy

Women with epilepsy who are pregnant or planning to be pregnant need additional guidance and care due to the complications…

Date: 28th July 2022

Managing migraine: gepants for acute and preventive treatment

Migraine is a debilitating disease with high clinical and social impacts. The calcitonin-gene-related peptide (CGRP) pathway has shown its importance…

Date: 20th July 2022

Latest developments in the treatment of motor fluctuations in Parkinson’s disease

Parkinson’s disease (PD) is the second most common neurodegenerative disorder in the world. This high prevalence of PD has put…

Date: 8th July 2022

Accelerating time to treatment: new approaches to pre-hospital and in-hospital stroke care

Stroke is a highly time-sensitive clinical event and as such, optimizing workflow is of critical importance, even before a patient…

Date: 1st June 2022

Updates in isolated RBD

Isolated RBD (iRBD) has been established as REM sleep behavior disorder without an associated neurodegenerative condition. However, RBD is commonly…

Date: 11th May 2022

Insight into the pathogenesis of pediatric-onset MOGAD

Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) is an inflammatory disorder mainly affecting the optic nerve, spinal cord, and brain. This…

Date: 11th May 2022

Optimizing clinical trial design for improved outcomes in multiple sclerosis

Measuring the efficacy of treatments for multiple sclerosis (MS) is challenging, due to the heterogeneity of disease presentation and the…

Date: 19th April 2022

Clinical trials in neuromuscular disorders: ALS, MG & SMA

Over the past few years, a number of novel treatments for neuromuscular disorders were approved and are now available to…

Date: 21st February 2022

Subtyping in Parkinson’s disease

It is well recognized that Parkinson’s disease (PD) can present with a broad spectrum of motor and non-motor symptoms, and…

Date: 2nd February 2022

Advances in stroke rehabilitation and recovery

Stroke is a leading cause of disability worldwide. Despite considerable improvements in acute stroke treatment, most patients are left with…

Date: 2nd February 2022